Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD146 Molecule Expression in B Cells Acute Lymphoblastic Leukemia (B-ALLs): A Flow-Cytometric Marker for an Accurate Diagnostic Workup.
Laganà A, Totaro M, Bisegna ML, Elia L, Intoppa S, Beldinanzi M, Matarazzo M, di Trani M, Costa A, Maglione R, Mandelli B, Chiaretti S, Martelli M, De Propris MS. Laganà A, et al. Among authors: matarazzo m. Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024064. doi: 10.4084/MJHID.2024.064. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 39258185 Free PMC article.
NG2 Molecule Expression in Acute Lymphoblastic Leukemia B Cells: A Flow-Cytometric Marker for the Rapid Identification of KMT2A Gene Rearrangements.
Bisegna ML, Peragine N, Elia L, Matarazzo M, Milani ML, Intoppa S, Di Trani M, Malfona F, Martelli M, De Propris MS. Bisegna ML, et al. Among authors: matarazzo m. Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024018. doi: 10.4084/MJHID.2024.018. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 38468826 Free PMC article.
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D, Beldinanzi M, Ansuinelli M, Elia L, Della Starza I, Bellomarino V, Matarazzo M, Di Trani M, Cola M, Salutari P, Cedrone M, Bassan R, De Gobbi M, Della Porta MG, De Simone M, Alati C, Fracchiolla NS, Lunghi M, Intermesoli T, Cardinali V, Mulè A, Guarini A, Foà R, Chiaretti S. Cardinali D, et al. Among authors: matarazzo m. Leuk Lymphoma. 2023 Nov-Dec;64(11):1884-1887. doi: 10.1080/10428194.2023.2235450. Epub 2023 Jul 15. Leuk Lymphoma. 2023. PMID: 37452789 No abstract available.
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.
Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A, Fazi P, Di Raimondo F, Santoro L, Fabbiano F, Califano C, Martinelli G, Ronco F, Ferrara F, Cascavilla N, Bigazzi C, Tedeschi A, Sica S, Di Renzo N, Melpignano A, Beltrami G, Vignetti M, Foa R. Chiaretti S, et al. Among authors: matarazzo m. Haematologica. 2021 Jul 1;106(7):1828-1838. doi: 10.3324/haematol.2020.260935. Haematologica. 2021. PMID: 33538150 Free PMC article.
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
Elia L, Grammatico S, Paoloni F, Vignetti M, Rago A, Cenfra N, Mecarocci S, Mancini M, Luciani M, Di Raimondo F, Cazzaniga G, Matarazzo M, Moleti ML, Santoro L, Gaidano G, Foà R, Mandelli F, Cimino G. Elia L, et al. Among authors: matarazzo m. Am J Hematol. 2011 Dec;86(12):993-7. doi: 10.1002/ajh.22161. Epub 2011 Sep 22. Am J Hematol. 2011. PMID: 21953510 Free article.
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
Torelli GF, Chiaretti S, Peragine N, Barberi W, Santodonato L, D'Agostino G, Abruzzese E, Del Principe MI, Mancino A, Matarazzo M, Bafti MS, Mancini M, Messina M, Castiello L, Guarini A, Foà R. Torelli GF, et al. Among authors: matarazzo m. Am J Hematol. 2022 Jun 1;97(6):E204-E207. doi: 10.1002/ajh.26537. Epub 2022 Mar 22. Am J Hematol. 2022. PMID: 35315128 Free article. Clinical Trial. No abstract available.
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S, Elia L, Peluso AL, Pedace L, Matarazzo M, Vitale A, Rago A, Pane F, Foà R, Cimino G. Grammatico S, et al. Among authors: matarazzo m. Leuk Res. 2009 Jul;33(7):e73-4. doi: 10.1016/j.leukres.2008.11.009. Epub 2008 Dec 23. Leuk Res. 2009. PMID: 19108887 No abstract available.
Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease.
Radefeldt M, Lemke S, Chaichoompu K, Paul JJ, Curado F, Valzania F, Cavallieri F, Fioravanti V, Valente EM, Avenali M, Negrotti A, Hanagasi HA, Thonke S, Matarazzo M, Panzavolta A, Cerami C, Westenberger A, Klein C, Bauer P, Beetz C. Radefeldt M, et al. Among authors: matarazzo m. Mov Disord. 2024 Oct 26. doi: 10.1002/mds.30041. Online ahead of print. Mov Disord. 2024. PMID: 39460989
191 results